RPg Family Wealth Advisory LLC Acquires Shares of 848 DexCom, Inc. (NASDAQ:DXCM)

RPg Family Wealth Advisory LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 848 shares of the medical device company’s stock, valued at approximately $57,000.

Other large investors also recently bought and sold shares of the company. Capital Insight Partners LLC raised its position in DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 90 shares in the last quarter. HM Payson & Co. raised its holdings in shares of DexCom by 6.0% in the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after purchasing an additional 100 shares in the last quarter. Clear Creek Financial Management LLC increased its holdings in DexCom by 4.2% during the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock valued at $336,000 after buying an additional 120 shares during the period. SeaCrest Wealth Management LLC raised its stake in DexCom by 3.6% in the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock worth $501,000 after buying an additional 152 shares in the last quarter. Finally, Securian Asset Management Inc. boosted its position in DexCom by 0.7% during the 2nd quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock valued at $2,593,000 after acquiring an additional 161 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on DXCM shares. Piper Sandler reissued an “overweight” rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. JPMorgan Chase & Co. increased their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Leerink Partners decreased their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Royal Bank of Canada dropped their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $78.10 on Thursday. The company’s fifty day moving average price is $71.11 and its 200 day moving average price is $88.51. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market capitalization of $30.51 billion, a PE ratio of 46.77, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,431 shares of company stock worth $399,319. Corporate insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.